{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:35:46Z","timestamp":1784064946567,"version":"3.55.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"projects of Sichuan Science and Technology Department","award":["2019YFS0196"],"award-info":[{"award-number":["2019YFS0196"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Clinical and basic research supports that blood glucose fluctuation is an important predictor of diabetic vascular disease and an etiology of lower extremity atherosclerosis, which is an important pathological basis for lower extremity vascular diseases. Previous Chinese National Natural Science Foundation trials (No. 81503566) have reported that the traditional Chinese medicine Shenqi compound can reduce blood glucose fluctuation and low-grade inflammation, and protect blood vessels; however, there are no high-quality clinical evidences available to support the same. This multicenter randomized controlled trial aims to obtain more clinical evidence to confirm the efficacy and safety of Shenqi compound in type 2 diabetes with lower extremity atherosclerosis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A multicenter RCT will be implemented in this study for a 32-week study period (8 weeks for intervention and 24 weeks for follow-up). Participants will be recruited from the Teaching Hospital of Chengdu University of TCM, Mianyang Hospital of TCM, and Shuangliu Hospital of TCM. Sixty participants will be randomly divided into a treatment group (basic treatment combined with traditional Chinese medicine Shenqi Compound) or a control group (basic treatment combined with Chinese medicine placebo) with 30 participants in each group. Patients will be selected considering the following inclusion criteria: age between 35 and 65 years, and a positive diagnosis for type 2 diabetes with lower extremity atherosclerosis and TCM syndromes. Primary outcome indicator is an arterial color Doppler ultrasound. Secondary outcome indicators include: blood glucose fluctuation indicators (MBG, SDBG, LAGE), islet \u03b2-cell function evaluation indicators (Homa-IR, Homa-islet, SG, SCP), inflammation indicators (NLR, CRP, IL-6), blood lipids, and HbA1c. Safety index includes vital signs (T, P, R, BP), blood, urine, stool routine, liver and renal function, electrocardiogram, and adverse event records. The endpoint event is defined as the presence of gangrene in the lower limbs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>Explore the clinical effect of traditional Chinese medicine \u201cShenqi Compound\u201d to reduce blood glucose fluctuation and use HOMA-IR, the area under the glucose curve, and the area under the C-peptide curve to evaluate the effect of protecting islet \u03b2 cell function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>: Chinese clinical trial registry (ChiCTR-1900027693). Registered on November 23, 2019. http:\/\/www.chictr.org.cn\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019501","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T06:53:55Z","timestamp":1584341635000},"page":"e19501","source":"Crossref","is-referenced-by-count":14,"title":["Traditional Chinese medicine Shenqi compound to improve lower extremity atherosclerosis of patients with type 2 diabetes by affecting blood glucose fluctuation"],"prefix":"10.1097","volume":"99","author":[{"given":"Qianru","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,3]]},"reference":[{"key":"R1-20230915","article-title":"Blood glucose fluctuations: new consensus, recognizing [J]","volume":"15","author":"Mu","year":"2018","journal-title":"Drug Evaluation"},{"issue":"(S1)","key":"R2-20230915","first-page":"220","article-title":"Research progress of TCM on blood glucose fluctuations [J]","volume":"51","author":"Zhang","year":"2017","journal-title":"Shanghai J TCM"},{"key":"R3-20230915","first-page":"146","article-title":"Dynamic blood glucose monitoring to evaluate the relationship between glycated hemoglobin, blood glucose fluctuations and hypoglycemia [J]","volume":"40","author":"Zheng","year":"2019","journal-title":"Sichuan Med J"},{"key":"R4-20230915","first-page":"4493","article-title":"Effect and mechanism of blood glucose fluctuations on macrovascular disease in patients with diabetes [J]","volume":"25","author":"Wang","year":"2019","journal-title":"Med Rev"},{"key":"R5-20230915","first-page":"173","article-title":"Correlation between blood glucose fluctuations and diabetic macrovascular complications [J]","volume":"30","author":"Duan","year":"2018","journal-title":"J Heart"},{"key":"R6-20230915","first-page":"3137","article-title":"Analysis of risk factors of atherosclerotic lesions in lower extremities with type 2 diabetes mellitus [J]","volume":"35","author":"Wang","year":"2019","journal-title":"Mod Med Health"},{"issue":"(6 Supplement 1)","key":"R7-20230915","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.ejvs.2019.06.664","article-title":"Cardiovascular disease remains the main cause of death in all peripheral arterial disease stages [J]","volume":"58","author":"Sigvant","year":"2019","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R8-20230915","first-page":"656","article-title":"Relationship between atherosclerosis grade and neutrophil\/lymphocyte ratio in lower extremities of type 2 diabetes patients [J]","volume":"18","author":"Wang","year":"2019","journal-title":"Chin J Multiple Organ Dis Elderly"},{"key":"R9-20230915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207683","article-title":"Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules","volume":"13","author":"Gao","year":"2018","journal-title":"PLoS One"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2174\/1871530319666190225113859","article-title":"Exploration of the effect and mechanism of ShenQi compound in a spontaneous diabetic rat model","volume":"19","author":"Liu","year":"2019","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R13-20230915","first-page":"292","article-title":"Chinese guidelines for the prevention and treatment of type 2 diabetes (2017 edition)","volume":"38","year":"2018","journal-title":"Chin J Pract Intern Med"},{"key":"R14-20230915","first-page":"1567","article-title":"Investigation on risk factors of lower extremity vascular disease in patients with type 2 diabetes","volume":"48","author":"Jia","year":"2019","journal-title":"Shaanxi Med J"},{"key":"R16-20230915","first-page":"326","article-title":"Application value of color Doppler examination of lower extremity arterial disease in patients with diabetes","volume":"17","author":"Yu","year":"2008","journal-title":"Shanghai Med Imaging"},{"key":"R17-20230915","first-page":"2614","article-title":"The value of color Doppler ultrasound combined with serum 25-hydroxyvitamin D_3 in evaluating lower extremity vascular disease of type 2 diabetes","volume":"43","author":"Yuan","year":"2014","journal-title":"Shanxi Med J"},{"issue":"(Z1)","key":"R19-20230915","first-page":"86","article-title":"Differences between dynamic and static indicators in evaluating islet \u03b2-cell function and insulin sensitivity","volume":"25","author":"Liu","year":"2011","journal-title":"Continuing Med Educ"},{"key":"R20-20230915","first-page":"1078","article-title":"Protective effect and mechanism of Shenqi compound prescription on vascular lesions in diabetic rats","volume":"34","author":"Hu","year":"2014","journal-title":"China J Integr Tradit Chin Western Med"},{"key":"R21-20230915","first-page":"71","article-title":"Analysis of the clinical effect of color Doppler ultrasound in diagnosing vascular disease of lower extremity with diabetes","volume":"25","author":"Liu","year":"2019","journal-title":"China Med Device Inform"},{"key":"R22-20230915","first-page":"1321","article-title":"Effects of acute blood glucose fluctuations on blood lipids in patients with type 2 diabetes","volume":"25","author":"Wang","year":"2010","journal-title":"Clin Metadata"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019501","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:57:25Z","timestamp":1694822245000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019501"}},"subtitle":["Study protocol for a randomized controlled multicenter trial"],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019501","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}